The cytogenetics of solid tumors

Linda D. Cooley, Kathleen S. Wilson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

All neoplasms have genetic abnormalities. Most neoplasms have visible nonrandom chromosome abnormalities. Interpretation of clonal chromosome anomalies and utilization of this knowledge can refine the histopathologic diagnosis of many tumors. The information gleaned from chromosome studies is in daily use by oncologists for patient care. The genetic data gathered by collaborative oncology groups advance chemotherapeutic regimens, which have, in turn, reduced mortality rates for many tumor types. The genetics of hematologic disorders has had a very significant clinical impact over the past several decades. The genetics of sarcomas, carcinomas, and central and peripheral nervous system tumors are used consistently today in pediatric diagnosis and management. There is an expanding influence of genetic information on the choice of therapeutic drugs for both adult and pediatric patients with solid tumors. Conventional cytogenetic analysis, fluorescence in situ hybridization (FISH) analysis, and now array CGH analysis of tumor tissues provide genetic data, which may improve the care and the therapeutics available for patients with benign and malignant neoplasms. This chapter discusses only those chromosomal abnormalities with a known impact on diagnosis, prognosis, or therapeutic response.

Original languageEnglish (US)
Title of host publicationThe Principles of Clinical Cytogenetics, Third Edition
PublisherSpringer New York
Pages371-411
Number of pages41
ISBN (Print)9781441916884, 9781441916877
DOIs
StatePublished - Jan 1 2013

Fingerprint

Cytogenetics
Tumors
Chromosomes
Pediatrics
Neoplasms
Chromosome Aberrations
Oncology
Neurology
Central Nervous System Neoplasms
Inborn Genetic Diseases
Cytogenetic Analysis
Peripheral Nervous System
Fluorescence
Fluorescence In Situ Hybridization
Tissue
Sarcoma
Patient Care
Therapeutics
Carcinoma
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Cooley, L. D., & Wilson, K. S. (2013). The cytogenetics of solid tumors. In The Principles of Clinical Cytogenetics, Third Edition (pp. 371-411). Springer New York. https://doi.org/10.1007/978-1-4419-1688-4_16

The cytogenetics of solid tumors. / Cooley, Linda D.; Wilson, Kathleen S.

The Principles of Clinical Cytogenetics, Third Edition. Springer New York, 2013. p. 371-411.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cooley, LD & Wilson, KS 2013, The cytogenetics of solid tumors. in The Principles of Clinical Cytogenetics, Third Edition. Springer New York, pp. 371-411. https://doi.org/10.1007/978-1-4419-1688-4_16
Cooley LD, Wilson KS. The cytogenetics of solid tumors. In The Principles of Clinical Cytogenetics, Third Edition. Springer New York. 2013. p. 371-411 https://doi.org/10.1007/978-1-4419-1688-4_16
Cooley, Linda D. ; Wilson, Kathleen S. / The cytogenetics of solid tumors. The Principles of Clinical Cytogenetics, Third Edition. Springer New York, 2013. pp. 371-411
@inbook{1f4a7e06fe4749709044533c2de476cd,
title = "The cytogenetics of solid tumors",
abstract = "All neoplasms have genetic abnormalities. Most neoplasms have visible nonrandom chromosome abnormalities. Interpretation of clonal chromosome anomalies and utilization of this knowledge can refine the histopathologic diagnosis of many tumors. The information gleaned from chromosome studies is in daily use by oncologists for patient care. The genetic data gathered by collaborative oncology groups advance chemotherapeutic regimens, which have, in turn, reduced mortality rates for many tumor types. The genetics of hematologic disorders has had a very significant clinical impact over the past several decades. The genetics of sarcomas, carcinomas, and central and peripheral nervous system tumors are used consistently today in pediatric diagnosis and management. There is an expanding influence of genetic information on the choice of therapeutic drugs for both adult and pediatric patients with solid tumors. Conventional cytogenetic analysis, fluorescence in situ hybridization (FISH) analysis, and now array CGH analysis of tumor tissues provide genetic data, which may improve the care and the therapeutics available for patients with benign and malignant neoplasms. This chapter discusses only those chromosomal abnormalities with a known impact on diagnosis, prognosis, or therapeutic response.",
author = "Cooley, {Linda D.} and Wilson, {Kathleen S.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4419-1688-4_16",
language = "English (US)",
isbn = "9781441916884",
pages = "371--411",
booktitle = "The Principles of Clinical Cytogenetics, Third Edition",
publisher = "Springer New York",

}

TY - CHAP

T1 - The cytogenetics of solid tumors

AU - Cooley, Linda D.

AU - Wilson, Kathleen S.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - All neoplasms have genetic abnormalities. Most neoplasms have visible nonrandom chromosome abnormalities. Interpretation of clonal chromosome anomalies and utilization of this knowledge can refine the histopathologic diagnosis of many tumors. The information gleaned from chromosome studies is in daily use by oncologists for patient care. The genetic data gathered by collaborative oncology groups advance chemotherapeutic regimens, which have, in turn, reduced mortality rates for many tumor types. The genetics of hematologic disorders has had a very significant clinical impact over the past several decades. The genetics of sarcomas, carcinomas, and central and peripheral nervous system tumors are used consistently today in pediatric diagnosis and management. There is an expanding influence of genetic information on the choice of therapeutic drugs for both adult and pediatric patients with solid tumors. Conventional cytogenetic analysis, fluorescence in situ hybridization (FISH) analysis, and now array CGH analysis of tumor tissues provide genetic data, which may improve the care and the therapeutics available for patients with benign and malignant neoplasms. This chapter discusses only those chromosomal abnormalities with a known impact on diagnosis, prognosis, or therapeutic response.

AB - All neoplasms have genetic abnormalities. Most neoplasms have visible nonrandom chromosome abnormalities. Interpretation of clonal chromosome anomalies and utilization of this knowledge can refine the histopathologic diagnosis of many tumors. The information gleaned from chromosome studies is in daily use by oncologists for patient care. The genetic data gathered by collaborative oncology groups advance chemotherapeutic regimens, which have, in turn, reduced mortality rates for many tumor types. The genetics of hematologic disorders has had a very significant clinical impact over the past several decades. The genetics of sarcomas, carcinomas, and central and peripheral nervous system tumors are used consistently today in pediatric diagnosis and management. There is an expanding influence of genetic information on the choice of therapeutic drugs for both adult and pediatric patients with solid tumors. Conventional cytogenetic analysis, fluorescence in situ hybridization (FISH) analysis, and now array CGH analysis of tumor tissues provide genetic data, which may improve the care and the therapeutics available for patients with benign and malignant neoplasms. This chapter discusses only those chromosomal abnormalities with a known impact on diagnosis, prognosis, or therapeutic response.

UR - http://www.scopus.com/inward/record.url?scp=84955746219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955746219&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-1688-4_16

DO - 10.1007/978-1-4419-1688-4_16

M3 - Chapter

AN - SCOPUS:84955746219

SN - 9781441916884

SN - 9781441916877

SP - 371

EP - 411

BT - The Principles of Clinical Cytogenetics, Third Edition

PB - Springer New York

ER -